Low-Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Childrens Oncology Group Report
American Journal of Transplantation, 08/09/2012
Clinical Article
Gross TG et al. – The data suggest rituximab combined with low–dose chemotherapy is safe and effective in treating pediatric with Epstein–Barr virus (+) posttransplant lymphoproliferative disease following solid–organ transplantation.



